JAMA Reviews What Actually Works for Low Back Pain in 619 Million Sufferers
A comprehensive JAMA review clarifies first-line treatments for acute and chronic low back pain, reshaping clinical practice.
Summary
Low back pain affects 619 million people worldwide and is the leading cause of disability globally. This JAMA review synthesizes current evidence on classification, risk factors, prognosis, and treatment. About 90% of cases are nonspecific, meaning no identifiable structural cause. Acute cases are often self-limiting, with 72% of patients recovering within 12 months. Chronic cases are harder to treat, though 42% still recover within a year. First-line care for acute pain includes heat, spinal manipulation, massage, acupuncture, NSAIDs, and muscle relaxants. For chronic pain, exercise of any type, cognitive behavioral therapy, and multidisciplinary programs take priority. NSAIDs are downgraded to second-line for chronic cases. The review emphasizes staying active, avoiding prolonged rest, and self-management as foundational strategies for all patients.
Detailed Summary
Low back pain is not merely a nuisance condition — it is the world's leading cause of years lived with disability, affecting an estimated 619 million people. This JAMA review consolidates the latest evidence on its epidemiology, classification, prognosis, and evidence-based management, offering a critical reference for both clinicians and informed patients.
The review defines low back pain as pain between the costal margin and the inferior gluteal fold, with or without leg involvement. Roughly 90% of presentations are nonspecific, meaning they lack an identifiable structural pathology such as fracture, infection, or malignancy. The condition is more prevalent in females and increases with age, peaking around 85 years. Key risk factors include obesity, depression, occupational physical demands, tobacco use, diabetes, and prior episodes.
On prognosis, the news is cautiously optimistic for acute cases: approximately 72% of patients recover within 12 months. Chronic low back pain is more resistant, yet 42% still achieve recovery within a year. Initial management across all durations centers on reassurance, expectation-setting, and encouraging patients to stay physically active rather than rest.
For acute nonspecific low back pain, first-line therapies include heat application, spinal manipulation, massage, acupuncture, NSAIDs such as ibuprofen, and skeletal muscle relaxants. For chronic cases, the hierarchy shifts: exercise of any type, cognitive behavioral therapy, and integrated multidisciplinary programs become first-line, with NSAIDs relegated to second-line status.
The clinical takeaway is clear: passive approaches and prolonged pharmacotherapy should be de-emphasized, particularly for chronic pain. Exercise and psychological interventions offer the strongest evidence base for long-term outcomes. Importantly, this review was published in JAMA ahead of print in 2026, representing the current state of consensus from leading pain researchers across UNSW, Oregon Health & Science University, and Yale.
Key Findings
- 90% of low back pain cases are nonspecific — no serious structural cause — and should not receive aggressive workup by default.
- 72% of acute low back pain patients recover within 12 months; even 42% of chronic cases resolve within a year.
- Exercise of any type is a first-line treatment for chronic nonspecific low back pain, alongside CBT and multidisciplinary care.
- NSAIDs and muscle relaxants remain first-line for acute pain but NSAIDs drop to second-line for chronic cases.
- Staying physically active and avoiding bed rest is recommended as foundational management regardless of pain duration.
Methodology
This is a narrative clinical review published in JAMA, synthesizing existing evidence on low back pain epidemiology, risk factors, prognosis, and management. It appears to follow a structured review format typical of JAMA Reviews, drawing on current guidelines and high-quality trial data. The full methodology, including search strategy and evidence grading, is available only in the complete article.
Study Limitations
This summary is based on the abstract only, as the full article is not open access; nuances in evidence grading and specific recommendation strength are unavailable. As a review article, its conclusions depend on the quality and selection of underlying studies, which cannot be fully assessed from the abstract alone. The review focuses on nonspecific low back pain and may not fully address management of specific spinal pathologies.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.